⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

September 1, 2024Annals of Surgery OpenOpen Access

Surgical Outcomes Following Neoadjuvant Treatment for Locally Advanced and Borderline Resectable Pancreatic Ductal Adenocarcinoma

Kai Tai Derek Yeung Sacheen Kumar David Cunningham Long R. Jiao Ricky H. Bhogal

View Full Paper

Ask AI

Bookmark

Share

Abstract

To assess overall survival (OS), compare the effects of neoadjuvant treatment, and describe surgical outcomes for patients undergoing pancreatic resection following chemotherapy and/or chemoradiotherapy (CRT) for borderline resectable (BR) or locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Yeung et al. (2024) studied this question.

synapsesocial.com/papers/68e59e9db6db64358753935d https://doi.org/10.1097/as9.0000000000000486

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Neoadjuvant Chemotherapy and Radiation Improves Recurrence-free and Overall Survival in Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma2024 · 2 citations
2Clinical Outcomes of Surgery After Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Ductal Adenocarcinoma2024 · 5 citations
3Chemotherapy with or without surgery for locally advanced or borderline resectable pancreatic ductal adenocarcinoma: A retrospective multicenter international study.2024
4Total Neoadjuvant Approach for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma—UK Tertiary Cancer Centre ExperienceCohort Study · 2026
5Surgical, Histopathological, and Quality of Life Outcomes Following Neoadjuvant Chemotherapy and Pancreatectomy for Borderline Resectable and Locally Advanced Pancreatic Cancer2025